Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
1986-4-1
|
pubmed:abstractText |
Thirty-seven patients with stage III non-small cell lung cancer were treated with the sequential administration of chemotherapy, consisting of Cisplatinum, VP-16 and Adriamycin, and radiotherapy. The response rate in 33 evaluable patients was 82 percent. The median survival for all evaluable patients was 11 months; 5 patients actually survived more than 24 months but all ultimately relapsed. It is concluded that treatment of advanced non-small cell lung cancer with the currently available tools is still unsatisfactory. Despite a high response rate our treatment protocol had only a modest impact on survival. Obviously, a concerted effort will be required to improve these results and will probably involve the development of new and better drugs.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0361-7742
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
201
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
133-9
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading | |
pubmed:year |
1985
|
pubmed:articleTitle |
Chemotherapy preceding radiotherapy in stage III non-small cell lung cancer.
|
pubmed:publicationType |
Journal Article
|